These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 7455970)

  • 1. Abnormal aggregation and increased size of platelets in myeloproliferative disorders.
    Cortelazzo S; Barbui T; Bassan R; Dini E
    Thromb Haemost; 1980 Jun; 43(2):127-30. PubMed ID: 7455970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormalities of epinephrine-induced platelet aggregation and adenine nucleotides in myeloproliferative disorders.
    Yamamoto K; Sekiguchi E; Takatani O
    Thromb Haemost; 1984 Dec; 52(3):292-6. PubMed ID: 6531753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormalities of platelet adenine nucleotides in patients with myeloproliferative disorders.
    Nishimura J; Okamoto S; Ibayashi H
    Thromb Haemost; 1979 Jun; 41(4):787-95. PubMed ID: 483250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood platelet calcium content and aggregation behaviour in myeloproliferative disorders and secondary thrombocytosis.
    Mindner K; Ostermann G; Hochhaus A; Höche D; Till U
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):461-4. PubMed ID: 2465953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The platelet defect in myeloproliferative disorder (author's transl)].
    Delobel J
    Nouv Rev Fr Hematol (1978); 1976; 16(3):443-6. PubMed ID: 1012918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defective platelet beta-N-acetyl hexosaminidase content and release in chronic myeloproliferative disorders.
    Emiliani C; Ciferri S; Mencarelli S; Mezzasoma AM; Momi S; Orlacchio A; Gresele P
    Platelets; 2006 Feb; 17(1):20-9. PubMed ID: 16308183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet abnormalities in myeloproliferative disorders.
    Holme S; Murphy S
    Clin Lab Med; 1990 Dec; 10(4):873-88. PubMed ID: 2272179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased response to arachidonic acid and U-46619 and resistance to inhibitory prostaglandins in patients with chronic myeloproliferative disorders.
    Cortelazzo S; Galli M; Castagna D; Viero P; de Gaetano G; Barbui T
    Thromb Haemost; 1988 Feb; 59(1):73-6. PubMed ID: 3129810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Selected parameters of blood platelet function in patients with myeloproliferative syndrome].
    Zuk E
    Ann Acad Med Stetin; 1998; 44():137-54. PubMed ID: 9857536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts: are they laboratory artefacts?
    Grignani C; Noris P; Tinelli C; Barosi G; Balduini CL
    Platelets; 2009 Mar; 20(2):131-4. PubMed ID: 19235056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal platelet function in myeloproliferative disorders.
    Waddell CC; Brown JA; Repinecz YA
    Arch Pathol Lab Med; 1981 Aug; 105(8):432-5. PubMed ID: 6894852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [ATP and ADP of platelets in chronic myeloproliferative disorders and multiple myeloma].
    Terada H; Ohshima M
    Rinsho Ketsueki; 1989 Jan; 30(1):22-8. PubMed ID: 2716195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Aggregative behavior and calcium content of platelets in thrombocythemia and thrombocytosis].
    Hochhaus A; Mindner K; Ostermann G; Höche D
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(6):765-70. PubMed ID: 1713878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Blood platelet function in chronic myeloid-type diseases. I. Myeloproliferative diseases].
    Cieslar P; Matousová O
    Vnitr Lek; 1987 Nov; 33(11):998-1009. PubMed ID: 3439041
    [No Abstract]   [Full Text] [Related]  

  • 15. [Blood platelet changes in myeloproliferative disorders].
    D'Angelo G; Calvano D; Giardini C
    Minerva Med; 1988 Oct; 79(10):853-7. PubMed ID: 3141845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
    Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
    Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo platelet release in myeloproliferative disorders.
    Ireland H; Lane DA; Wolff S; Foadi M
    Thromb Haemost; 1982 Aug; 48(1):41-5. PubMed ID: 6215739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelets in myeloproliferative disorders. I. A comparative evaluation with certain platelet function tests.
    Boneu B; Nouvel C; Sie P; Caranobe C; Combes D; Laurent G; Pris J; Bierme R
    Scand J Haematol; 1980 Sep; 25(3):214-20. PubMed ID: 7466310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Platelet defects in chronic myeloproliferative disorders].
    Raszeja-Specht A; Skibowska A; Kabata J; Hellmann A
    Acta Haematol Pol; 1994; 25(3):253-60. PubMed ID: 7992598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy.
    Ryningen A; Apelseth T; Hausken T; Bruserud Ø
    Platelets; 2006 Aug; 17(5):296-302. PubMed ID: 16928601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.